A new breakthrough energy-based cancer therapy has the ability to kill cancer cells with no side effects in five different cancer cell types: breast, prostate, and the pancreas. This new therapy induces rapid cell death in over 80% in just two hours. It utilizes a drug combined with a certain light wavelength to produce a chemical reaction, then injected into a cancerous tissue, which disseminates, resulting in high acidity in the cancer cells, and eventually, death. The drug mixed with their technology shows no adverse side effects and been successful at killing different types of cancer cells in their petri…
Browsing: Uncategorized
A real-time, in vivo imaging platform guides surgeons during cancer surgery. This breakthrough technology illuminates cancer cells and other diseased tissues at the molecular level, allowing surgeons to take action and better patient outcomes. Currently, there is a technological gap at the molecular level. Surgeries are being completed without being able to distinguish between healthy and cancerous tissue. This technology solves the problem, so surgeons can complete their surgeries with the ability to differentiate between tissues and have better accuracy in removing all cancerous tissue. Currently, the company is focused on breast cancer in their testings, but want to continue…
The Cancer Progress Report delivers crisp headlines of progress at emerging companies developing, in many cases, breakthroughs. It is a fast and efficient must read for anyone serious in the field. For companies it provides an economical means to accomplish the critical function of reaching and keeping the important informed as to progress. Editorial Content has three themes: Introductions to New Members Introduction to the company and what makes it unique. This 40 words linked to the Altru Cancer website and the company site for a full profile. Ongoing Coverage Member Progress. Update on newsworthy developments. Headline and first sentence…
Immuno-oncology focusing on women’s cancers Technology Although cancer therapies have been developed that stimulate the immune system, these approaches have often proven ineffective because the cancers remain invisible to the immune system. Cancers cannot induce an immune response because they no longer express sufficient levels of key proteins on their cell surface. Antigen presentation is impaired thus presenting a weakened signal to which the cellular immune system can respond. The company’ peptide antigens can stimulate both T-killer cells and T-helper cells. When combined with its Polystart expression vector provides a competitive edge in the in vivo T-cell vaccine sector. Clinical…
Technology CEL-SCI Corporation is a late-stage biopharmaceutical company developing products for life-threatening diseases (such as cancer and infectious diseases). Its lead pipeline product – Multikine investigational immunotherapy (Leukocyte Interleukin, Injection) is a complex biological product containing a patented mixture of pro-inflammatory cytokines, lyphokines and chemokines. The aim of the Multikine immunotherapy treatment regimen is to break tumor-tolerance and up-end the tumor’s defense mechanisms by increasing tumor–specific infiltrating T-cells, NK cells and Neutrophils in the tumor and its microenvironment. The Multikine regimen is administered prior to any other therapy (immediately after diagnosis) when the immune system is thought to be most amenable…
NFCR Press Release NFCR Writer David Perry August 6, 2018 In 2016, archeologists working in the Swartkrans Cave in South Africa found a piece of foot bone belonging to a hominid dating back 1.6 to 1.8 million years. This alone would create a buzz among scientists. But it was what was on the bone that generated headlines: This ancient human had osteosarcoma, or bone cancer. It is the earliest example of cancer yet found. It may be commonsensical to think that if a malady has been in the human genome that long, and probably even longer, evolution would have produced…
NFCR Press Release NFCR Writer David Perry August 6, 2018 In an attempt to bolster the numbers of minorities in cancer research, the Cleveland-based Case Western Reserve University School of Medicine (CaseMed), in partnership with the Case Comprehensive Cancer Center, was awarded a five-year grant, totaling $2.5 million to engage local underrepresented youth. The funding went to the creation of the Youth Enjoy Science (YES) Program and is the first and only program at CaseMed to provide a comprehensive and integrated approach to cancer research training, spanning middle school through high school, and extending to college undergraduates. “There is currently…
NCI Press Release July 17, 2018 The largest coordinated research effort to study biological and non-biological factors associated with aggressive prostate cancer in African-American men has begun. The $26.5 million study is called RESPOND, or Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress. It will investigate environmental and genetic factors related to aggressiveness of prostate cancer in African-American men to better understand why they disproportionally experience aggressive disease—that is, disease that grows and spreads quickly—compared with men of other racial and ethnic groups. RESPOND is supported by the National…